Objective: To determine whether the immune score and methylation levels of transcription factor 21 (TCF21) could be used as independent diagnostic indicators and prognostic predictors in prostate cancer (PCA). Study Design: A descriptive study. Place and Duration of Study:Department of Urology, Quanzhou First Hospital A liated to Fujian Medical University, from November 2017 to December 2019. Methodology: Cases of PCA were for numbers of CD3+ and CD8+ T lymphocytes in the nests and stromal regions of PCA tissues. The percentage of CD8+ T lymphocytes in the peripheral blood was measured. TCF21 methylation was detected. The patient samples were classi ed according to risk-factor level, the immune score aTnCdF21 methylation levels were subsequently determined. The time of e ective hormone therapy was calculated. The relationships among immune scoTrCeF,21 methylation level, PCA risk-factor level and the time of e ective hormone therapy were determined. Results: There was no signi cant di erence of the proportions of CD8+ T cells in the peripheral blood between di erent T stage groups and di erent Gleason scores groups. The authors found negative linear relationships between immune score and risk-factor level, PSA level and Gleason score (p 0.05). The immune score correlated with the time of e ective hormone therapy (p =0.002). There was signi cant correlation between TCF21 methylation and PSA, Gleason score, risk-factor level and immune score (p 0.05). Conclusion: The immune score and TCF21 methylation could be used as independent indicators for the diagnosis and prognosis of PCA.